YUTREPIA sales surge as patent litigation is permanently settled
- Liquidia is a commercial biotech company focused on rare cardiopulmonary diseases.
- YUTREPIA net sales reached $222.7 million in the third quarter of 2026.
- The company permanently settled its patent litigation with United Therapeutics.
- Liquidia faces a $380 million cash settlement payment due by April 2027.
- Management expects to generate more than $1 billion in net revenue by 2027.
From courtroom drama to a pure execution play
Liquidia has transitioned from a high-stakes litigation story to a pure commercial execution story. The dominant near-term overhang, the United Therapeutics patent litigation, has been fully resolved via a settlement. This secures YUTREPIA's future without ongoing royalties.
YUTREPIA continues its massive commercial ramp, posting $222.7 million in third-quarter net sales in 2026. The bull case is anchored by rapid market share gains in the PAH segment and a deep pipeline of clinical trials to expand into massive new markets.
Bear concerns are now restricted to financial execution and competition. The company must navigate a $380 million cash settlement payment through April 2027 while fending off aggressive competitor marketing tactics.
Pure commercial execution and funding a pipeline
Liquidia makes money primarily through direct U.S. sales of YUTREPIA, an inhaled dry powder form of treprostinil. A small secondary source is a profit-sharing agreement with Sandoz for a generic Treprostinil Injection.
Following a permanent settlement with United Therapeutics, YUTREPIA's market availability is fully secured with no ongoing royalties owed. This shifts the model purely to commercial execution and scaling.
The financial model is facing a new reality on margins. The company has sold through all its pre-approval zero-cost inventory. Future product sales will now reflect the full cost of manufacturing, which will compress gross margins even as top-line revenue scales.
Treprostinil, several forms
YUTREPIA for PAH and PH-ILD
Approved and commercialized for pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease.
YUTREPIA lifecycle expansion
The company is planning new clinical studies for PH-COPD, IPF, progressive pulmonary fibrosis, and systemic sclerosis.
Treprostinil Injection
A generic version of Remodulin sold with Sandoz. Growth is severely limited because the required CADD-MS 3 infusion pump is discontinued.
L606
An investigational twice-daily inhaled liposomal treprostinil product. It is currently in a global pivotal study for PH-ILD.
Revenue is dominated by YUTREPIA
Liquidia does not present classic business segments. This mix relies on reported revenue lines, reflecting the massive recent scale-up of YUTREPIA product sales against constrained Sandoz service revenue in late 2026.
What could break the story
Massive settlement obligation
High impact · High oddsThe United Therapeutics litigation is settled, but Liquidia now faces a massive one-time charge. Over $380 million is payable in cash through April 2027, putting intense pressure on the balance sheet.
Gross margin compression
Medium impact · High oddsLiquidia has sold through its pre-approval zero-cost inventory for YUTREPIA. Future sales will carry the full weight of manufacturing costs, reducing gross margins.
Growth sustainability
High impact · Medium oddsThe financial plan depends heavily on YUTREPIA becoming a massive commercial success. If prescriptions or insurance coverage fall short of the $1 billion target for 2027, the stock will suffer.
Market competition
Medium impact · High oddsYUTREPIA competes with established inhaled therapies like Tyvaso and new drug classes like Merck's Winrevair. Liquidia needs to convince doctors to switch patients to its dry powder inhaler.
In one breath
What does Liquidia sell?
Liquidia sells YUTREPIA, an inhaled dry powder form of treprostinil for PAH and PH-ILD. It also earns service revenue from promoting Sandoz's generic Treprostinil Injection in the U.S.
Why is Liquidia considered speculative?
The company relies almost entirely on one newly launched drug and faces a massive cash settlement payment. While YUTREPIA is generating significant revenue, any stumble in sales could strain the balance sheet.
What is PRINT technology?
PRINT is Liquidia's particle engineering technology. It is used to make drug particles with a uniform size and shape, allowing medicine to reach deep into the lungs.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 15, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Liquidia Corporation in Finn's Biotechnology industry ranking.

